On February 24, 2014 DNAtrix was awarded a product development grant for $10.8 million to fund the company’s clinical-stage program in glioblastoma (Press release DNAtrix, FEB 24, 2014, View Source [SID:1234500126]). The grant from the Cancer Prevention and Research Institute of Texas (CPRIT) is entitled "Clinical development and commercialization of oncolytic adenovirus for treating malignant glioma."
The grant awarded to DNAtrix will be used to drive the clinical development of DNX-2401, the lead product candidate that is currently undergoing a Phase Ib trial in combination with temozolomide for recurrent glioblastoma. DNX-2401 uses a genetically modified adenovirus that kills tumor cells selectively. In an earlier Phase I study in recurrent glioblastoma, DNX-2401 demonstrated an excellent safety profile and promising efficacy results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

m013 is a mixture of six humanized full length monoclonal antibodies targeting EGFR, HER2 and HER3 which is under development by Symphogen for the treatment of cancer (Company Pipeline Symphogen, FEB 22, 2014, View Source [SID:1234500115]).

Sym014 belongs to an antibody drug conjugate program against undisclosed receptor tyrosinekKinase target.which is under development by Symphogen for the treatment of leukemia (Company Pipeline Symphogen, FEB 22, 2014, View Source [SID:1234500116]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sym015 is a multi targeting mAb mixture program against undisclosed receptor tyrosine kinase target and stromal target which is under development by Symphogen for the treatment of cancer (Company Pipeline Symphogen, FEB 22, 2014, View Source [SID:1234500117]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Sym013 is a mixture of six humanized full length monoclonal antibodies targeting EGFR, HER2 and HER3 which is under development by Symphogen for the treatment of cancer (Company Pipeline Symphogen, FEB 22, 2014, View Source [SID:1234500115]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!